SGLT2‑Inhibitor Therapy for Heart Failure with Preserved Ejection Fraction (HFpEF)
1. Guideline Recommendation
Start an SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) in any adult with HFpEF and an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m², irrespective of diabetes status. 1
2. Evidence Strength & Supporting Guidelines
The 2025 Canadian Cardiovascular Society/Canadian Heart Failure Society guideline assigns a Class I (strong) recommendation to SGLT2 inhibitors for HFpEF, based on high‑quality randomized trial data. 1
The 2022 ADA Standards of Care also recommends SGLT2 inhibitors for HF (both reduced and preserved ejection fraction) to prevent HF hospitalizations, regardless of glycemic status. 2
3. Drug Choice and Dose
Only the 10 mg daily dose of dapagliflozin or empagliflozin has been tested in outcome trials for HFpEF and is FDA‑approved for this indication; no dose titration is required. 1
4. Renal Function Threshold for Initiation
Therapy should be initiated when eGFR ≥ 30 mL/min/1.73 m². [1][5]
Data supporting use below this threshold in HFpEF are limited. 5
5. Pre‑Initiation Assessment
5.1 Volume Status & Diuretic Management
Assess volume status and, in patients at risk for hypovolemia (e.g., elderly, low systolic BP, high diuretic dose), reduce loop diuretic dose by approximately 30–50% before starting an SGLT2 inhibitor. [6][7]
5.2 Renal Monitoring
An acute, reversible eGFR decline of ~2–5 mL/min/1.73 m² (≈3–6 %) is expected within the first 2–4 weeks and does not indicate kidney injury. 6
Re‑measure eGFR at 2–4 weeks after initiation and subsequently every 3 months; no additional testing frequency is required. 6
5.3 Glycemic Management (for patients with diabetes)
If glycemic targets are already met, reduce insulin dose by ~20 % or lower sulfonylurea dose to avoid hypoglycemia; SGLT2 inhibitors rarely cause hypoglycemia when used without insulin or secretagogues. 7
6. Safety Considerations & Patient Education
6.1 Genital Mycotic Infections
Genital mycotic infections occur in ~6 % of SGLT2‑inhibitor users versus ~1 % with placebo; counseling on genital hygiene reduces risk, and infections are usually mild and treatable without stopping the drug. [6][5]
6.2 Euglycemic Diabetic Ketoacidosis (DKA) Prevention
Temporarily hold SGLT2 inhibitors during prolonged fasting, major surgery (≥3 days pre‑op), or acute critical illness (e.g., severe infection, dehydration, COPD exacerbation) to lower the risk of euglycemic DKA. [9][6]
Patients should be instructed to discontinue the drug and seek urgent care if they develop nausea, vomiting, abdominal pain, or malaise, which may signal ketoacidosis even with normal glucose. 6
6.3 Volume Depletion
Monitor for signs of dehydration, especially during the first month, as SGLT2 inhibitors increase urinary glucose and sodium excretion causing modest osmotic diuresis; risk is higher in patients on high‑dose diuretics or with baseline hypotension. [6][7]
7. Expected Clinical Benefits
HF hospitalizations are reduced by approximately 21–27 % (absolute risk reduction 2.7–3.3 % over 2–3 years) in HFpEF patients treated with dapagliflozin or empagliflozin. 1
Quality of life improves modestly, with mean Kansas City Cardiomyopathy Questionnaire scores increasing by 5–10 points. 1
In chronic kidney disease cohorts, the chronic eGFR decline is slowed by ~50 % (≈1.4 mL/min/1.73 m² per year slower) when SGLT2 inhibitors are used. 8
8. Contraindications & Cautions
Absolute contraindications: chronic dialysis dependence, type 1 diabetes, and serious hypersensitivity reactions. 4
Recurrent genital infections are a cautionary factor but not a contraindication; they can be managed with hygiene measures and appropriate antifungal therapy. 4